Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry

This study by Karakas, et al. found that obesity did not affect secukinumab treatment response and drug retention in ankylosing spondylitis patients.

Patients included in the study had ankylosing spondylitis according to ASAS who has previously used secukinumab. The primary endpoint was BASDAI50 response at 6 months; univariate and multivariate analyses revealed that obesity does not affect BASDAI50 response at 6 months.